jRCT stands for Japan Registry of Clinical Trials. It is Japan's government-run public registry for clinical trials and other clinical research, managed by the Ministry of Health, Labour and Welfare (MHLW). It publishes study information, including legally required notifications, so people can check what research is planned or underway and any results that have been posted. En topJrct_registry_profile.pdf Registration is not treatment approval or proof that an intervention works.
On 24 October 2026, the English search page listed 17,641 study records. The figure counts records, not approvals. Search?language=en

A jRCT number helps you find a particular study. To evaluate a clinic's claim, match that study's condition, intervention, recruitment status, and results to what the clinic is offering.
What a jRCT number means
The Japanese name translates roughly to the Clinical Research Submission and Publication System. En top A jRCT number is a record identifier. Read the entry itself for its study category, phase, and status; do not treat the number as a quality score or an approval certificate.
Who runs jRCT
MHLW operates the registry, but sponsors and investigators conduct the studies. jRCT does not run trials, enroll patients, or provide treatment. Questions about joining a study go to the trial office named in the record, not to the registry. En topJrct_registry_profile.pdf
jRCT joined the WHO primary registry network in December 2018. 05 12 2018 japan registry for clinical trials (jrct) Membership reflects reporting standards and does not rate study quality.
Why studies are registered
Japan's Clinical Trials Act took effect in April 2018. Its specified clinical trial category includes research funded by the marketing-authorization holder of the product being studied, or a related party, and research using certain unapproved or off-label drugs, devices, or regenerative medical products. Designated off-label uses with the same or lower risk than approved use are excluded from the off-label category. Covered studies require certified review board review and submission of an implementation plan to MHLW. En
The Act on the Safety of Regenerative Medicine (ASRM), effective November 2014, establishes a separate framework for covered care and research, including processed-cell interventions. Its scope also includes certain gene therapies that do not use processed cells. Requirements depend on the technology and risk class. En
A third legal route runs through the Pharmaceuticals and Medical Devices Act (PMD Act), which governs marketing authorization of drugs, devices, and regenerative medical products. En An MHLW notification requires jRCT registration for newly notified drug trials from 1 September 2020, excluding the specified bioequivalence studies. 000236406.pdf Registration of such a trial is not product approval.
For ASRM submissions, MHLW directs research plans to jRCT and treatment plans to e-Saiseiiryo, a separate system. The amended law took effect on 31 May 2025; filing a plan still does not confer marketing authorization. Index
What is inside a record
A jRCT record contains fields from the WHO Trial Registration Data Set plus Japan-specific fields. The registry accepts interventional and observational studies. Jrct_registry_profile.pdf Not every record is a trial of a new treatment.
| Record type | Legal route | Who files | Where it appears | What the record means |
|---|---|---|---|---|
| Specified clinical trial | Clinical Trials Act | Investigator or sponsor, with a certified review board and MHLW | jRCT | A reviewed research plan, not an approval |
| Non-specified clinical trial | Clinical Trials Act | Research team, with ethics review | jRCT, when registered | A research record; obligations depend on the study |
| Trial for marketing approval | PMD Act | Company or investigator | jRCT | An investigational trial, not an approval |
| Post-marketing trial or survey | PMD Act | Company | jRCT | Study information, not an additional marketing approval |
| Regenerative medicine research | ASRM Act | Research team, through a committee and regulator | jRCT | Research, not a treatment plan |
| Regenerative medicine treatment | ASRM Act | Clinic, through a committee and regulator | e-Saiseiiryo | A filed treatment plan, not efficacy approval |
| Observational study | Applicable ethics and research rules | Research team | jRCT or UMIN-CTR | Does not assign the intervention being studied; associations need careful interpretation |
The treatment row is included for comparison: it belongs to e-Saiseiiryo, not jRCT. The other categories have different review and reporting duties. En topJrct_registry_profile.pdfIndex
A record usually covers title, condition, intervention, phase, sample size, eligibility, outcomes, recruitment status, sponsor, dates, and any results summary. A blank field can mean the item does not apply, the sponsor has not updated it, or the record migrated from an older registry. En top The trial office can clarify which reason applies.
What registration cannot establish
Regenerative medicine treatment plans are in e-Saiseiiryo, not jRCT. Index Its public list shows the institution, treatment name, committee, and consent documents, in Japanese. 1
jRCT is not the authoritative list of marketing approvals. Check the relevant MHLW approval and PMDA review documents for the specific product and indication. 000280868.pdf A registration can describe a planned study, so it does not even establish that testing has been completed.
Not every Japanese study is in jRCT. UMIN-CTR serves many academic researchers with some overlap, and some company trials also appear on ClinicalTrials.gov. EnClinicaltrials.govCtr A broader search should cover all three registries.
The information comes from study teams. Registry checks are not peer review of a completed scientific paper or an independent assessment of treatment benefit. Jrct_registry_profile.pdf
How to read a record
Read both the public and scientific titles, then the design and intervention fields. Terms such as "randomized," "double-blind," and "placebo-controlled" describe methods; they do not tell you whether the study succeeded.
| Field | What it tells you | What it does not tell you |
|---|---|---|
| Condition and stage | Disease, sometimes severity or prior treatment | Whether the study fits you |
| Population and eligibility | Age, diagnosis, prior therapies, exclusions | Whether the team will accept you |
| Intervention | Product, cell type, source, dose, route, schedule | Whether the intervention works |
| Phase | Development stage | That a later phase will succeed |
| Design | Randomization, blinding, comparator, arms | That the design was well executed |
| Target sample size | Planned enrollment | Actual enrollment |
| Primary outcome | The main question the study answers | Whether the result is clinically meaningful |
| Follow-up and completion | Planned observation period and study dates | How long each participant was actually followed |
| Results and adverse events | Reported findings, if posted | That all harms were captured |
| Sponsor and contact | Funder and inquiry point | That the sponsor's claim is independent |
Consider a hypothetical record with a target enrollment of 100 and actual enrollment of 28. It enrolled 28 people, not 100; the number treated or included in each outcome analysis may be smaller. Check the results report for those denominators, withdrawals, comparator group, and follow-up. This is an illustration, not a reported patient series.
The primary outcome may be a marker, imaging change, symptom score, or survival time. A marker change is not automatically a clinical benefit. For a cell intervention, also match the disease and stage, age group, cell source and type, dose, and administration route before applying findings to another treatment.
In drug development, Phase 1 usually emphasizes safety and dose; Phase 2 investigates activity and further safety; Phase 3 generally tests benefit against a comparator in a larger group; Phase 4 follows approval. How trials work These labels do not apply to every study. A Phase 1 registration alone does not establish efficacy.
A missing results summary can mean ongoing research, unfinished analysis, no update, or publication elsewhere. Read adverse events alongside benefit results. A serious event needs investigation, but its occurrence alone does not prove that the intervention caused it. Likewise, absent harm data do not establish safety. A linked publication must be assessed on its methods and results; PubMed indexing alone is not a quality guarantee.
How to search
Use the official English jRCT search; searching public records does not require an account. En top
- If you have a jRCT number, use the full identifier to locate the entry and confirm it matches. Otherwise try the disease or intervention, then synonyms such as "mesenchymal stem cell" and "MSC."
- Use advanced search to limit broad results by study category, recruitment status, and institution.
- Check registration and last-modified dates; a record untouched for years may be stale.
- Note sponsor and contact for who paid and where to ask.
- Cross-check the jRCT number in the JPRN portal, which covers jRCT and UMIN-CTR together, plus ClinicalTrials.gov where relevant. EnClinicaltrials.gov
- For eligibility, write to the contact named in the record and cite the full jRCT number with your access date.
The registry collects Japanese and English information, but do not assume that every supporting document is translated. Jrct_registry_profile.pdf Ask the study team for an explanation in a language you understand before signing consent.
jRCT versus other systems
Each system answers a different question. En topEn
| System | Who runs it | Best for | Not for |
|---|---|---|---|
| jRCT | MHLW | Japanese clinical research, including statutory filings and observational studies | A complete list of every Japanese study, or a treatment approval list |
| UMIN-CTR | University Hospital Medical Information Network | Academic, observational, and investigator-led studies | MHLW regulatory filings |
| ClinicalTrials.gov | U.S. National Library of Medicine | International trials, including some Japanese sites | Japanese legal status or treatment plans |
| WHO ICTRP | World Health Organization | Cross-searching participating registries | A substitute for the original record |
| JPRN | MHLW and the National Institute of Public Health | Searching jRCT and UMIN-CTR in one place | Registering a trial; it is a portal, not a registry |
| e-Saiseiiryo | MHLW | Filed regenerative medicine treatment plans | Research records or marketing approvals |
JPRN is a search layer, not a registry. Follow any hit back to its original record before relying on it.
The regenerative medicine distinction
jRCT, e-Saiseiiryo, and product approval documents answer different questions. A research registration should not be substituted for the documents governing a treatment service.
ASRM regulates the provision of covered medical technologies, whereas the PMD Act governs manufacture and marketing authorization of regenerative medical products. EnEn000280868.pdf
For an ASRM treatment service, ask for the applicable e-Saiseiiryo plan; for an approved product, ask for its approval and approved indication. An ASRM research team should identify its research record. Index000280868.pdf This distinction is also the starting point for registration and compliance checks in Japan.
A committee's review is not merely a paperwork check: MHLW guidance calls for consideration of scientific validity, including the prospect of effectiveness. That review and the filing of a plan are nevertheless different from product marketing authorization and do not prove benefit for an individual patient. 001253739.pdf As of 20 May 2026, PMDA's presentation showed 26 approved regenerative medical products, including conditional and time-limited approvals; this is not a count of all stem cell services offered in Japan. 000280868.pdf
A practical document check
When checking MHLW's official procedures page for this guide on 27 October 2026, we found separate links for treatment-plan submission through e-Saiseiiryo and research-plan submission through jRCT. The labels explicitly distinguish treatment from research. Index
Suppose a clinic offers a paid cell intervention and provides only a research number. First ask whether you are being invited into that study or offered a separate clinical service. Then request the documents for that actual route. Payment by itself does not determine whether an intervention is research, approved care, or a private service.
What the numbers mean
The WHO registry profile reported 15,106 trials as of 30 July 2025. Jrct_registry_profile.pdf That is a different date and label from the English search page's 17,641 study records on 24 October 2026. En top Do not subtract the figures to calculate growth or interpret either as the number of treatments available.
For historical context, a 2022 retrospective database study reported 577 specified clinical trials in jRCT and 5,068 trials in UMIN-CTR for April 2018 through March 2020. PMC9297204
The 2022 study was a retrospective database analysis, not a trial. It excluded marketing-authorization trials and regenerative medicine studies, so 577 versus 5,068 is not a complete count of Japanese research, nor a like-for-like measure across different registry scopes and rules. PMC9297204 Registry counts are not quality scores.
Checking a jRCT number in an ad
Ask for the exact number, open it during the conversation, and check five things.
- Record type. Establish whether the number identifies research, and ask separately for any applicable treatment-plan or product-approval documents.
- Status. Check whether it is recruiting, suspended, or complete. A completed study is not an open invitation to enroll; it does not determine whether the intervention is available by another lawful route.
- Match. Compare disease, population, cell type, route, and sponsor with the ad. A different indication or product does not support the claim.
- Results. Read the primary outcome and adverse events, not just the conclusion. If no summary is posted, ask why.
- Scope. One record for one study cannot support every service at a clinic.
"jRCT-approved" is not a status. "Registered in jRCT" does not mean proven effective, and "Phase 1 study" does not mean available treatment. A mismatch is not automatic fraud, but it is a reason to slow down and ask for the document. The same document checks apply when comparing hospitals in Japan before committing to treatment.
Limits of the registry
Records come from sponsors and investigators. Checks for completeness and meaningfulness are not an independent audit of every participant's clinical data. Jrct_registry_profile.pdf A correctly registered study can still have a weak design, a small sample, or unpublished results.
The last-modified date identifies a registry update, not necessarily the date of a clinical event. MHLW's FAQ gives a usual publication-checking period of 7 to 10 days, sometimes 10 days to two weeks depending on workload. Faq Confirm recruitment directly with the team rather than treating a status field as a live appointment system.
For migrated JapicCTI records, the FAQ explains that a "pending" study-type category can reflect migration, not recruitment status. Faq The English site also restricts automated downloading beyond personal use; consult its data-use notice before bulk collection. En top
Bottom line
Japan's jRCT is a public research registry, not a treatment-approval list. Its English search page displayed 17,641 records on 24 October 2026, while the WHO profile reported 15,106 trials on 30 July 2025. En topJrct_registry_profile.pdf Separately, PMDA's presentation showed 26 approved regenerative medical products as of 20 May 2026. 000280868.pdf These are different measures, not interchangeable evidence of efficacy.
Use the registry to settle what a jRCT entry is, then ask a clinician who can examine you whether the evidence applies to your case.
This article is general education, not medical advice, diagnosis, or a recommendation of any clinic or product. Trial or treatment eligibility is decided by the clinical team after examination and informed consent.
Have a jRCT number you want checked?
If you have questions about the documents for a proposed service, contact our team with the public record number and the claim you want clarified. For trial eligibility, contact the study team named in the record.
Sources
The search-page count is a dated snapshot, not a live total. Key regulatory documents were rechecked on 27 October 2026. Some sources are Japanese-only; English legal translations are for reference, and the Japanese text controls. The retrospective registry study is used for historical counts, not clinical efficacy evidence.
The publisher of this site provides medical consultation services, which is a commercial interest.
| # | Source and link | What it supports | Date and scope |
|---|---|---|---|
| En top | jRCT official English top page, FAQ, and search page | Registry purpose, search, data-use notice, publication timing, migration; historical 17,641-record snapshot | Count accessed 24 Oct 2026; top page and FAQ rechecked 27 Oct 2026; Japan |
| Jrct_registry_profile.pdf | WHO ICTRP Registry Profile: jRCT | Management, scope, 15,106 trials, Japanese and English data, WHO data set | Profile completed 30 Jul 2025; Japan |
| 05 12 2018 japan registry for clinical trials (jrct) | WHO: New member of the Primary Registry Network | jRCT joined the WHO network in December 2018; Clinical Trials Act basis | 5 Dec 2018; Japan |
| En | Clinical Trials Act, English translation | Legal framework for specified clinical trials | Act No. 16 of 2017; Japan |
| En | Act on the Safety of Regenerative Medicine, English translation | Safety and bioethics framework for regenerative medicine | Act No. 85 of 2013; Japan |
| En | Pharmaceuticals and Medical Devices Act, English translation | Legal framework for product marketing authorization | Act No. 145 of 1960; translation reflects an older version; Japan |
| 000236406.pdf | MHLW notification on trial registration, via PMDA | jRCT registration required for newly notified drug trials from 1 Sep 2020, excluding bioequivalence studies | 31 Aug 2020; Japanese |
| Index | MHLW: Regenerative and cell medicine, legal updates, and committee review guidance | Research/treatment submission routes; 31 May 2025 amendment; scientific validity and prospect of effectiveness | Rechecked 27 Oct 2026; Japan; Japanese |
| 1 | e-Saiseiiryo: published treatment plans | Public list of filed regenerative medicine treatment plans | Accessed 24 Oct 2026; Japan; Japanese |
| 000280868.pdf | PMDA: Japan's regulatory framework for regenerative medical products | Two-law framework; 26 approved regenerative medical products as of 20 May 2026 | 20 May 2026; Japan |
| En | JPRN search portal | Cross-search of jRCT and UMIN-CTR | Accessed 24 Oct 2026; Japan |
| Clinicaltrials.gov | ClinicalTrials.gov | International trial registry | Accessed 24 Oct 2026; international |
| Ctr | UMIN Clinical Trials Registry | Academic trial registry run by the University Hospital Medical Information Network; registration and search system | Accessed 27 Oct 2026; Japan |
| How trials work | NCI: How Do Clinical Trials Work? | Trial phases 1–4: safety and dose, early benefit signals, comparison with standard therapy, post-approval follow-up | Accessed 27 Oct 2026; international |
| PMC9297204 | Impact of the Clinical Trials Act 2018 on clinical trial activity in Japan | 577 specified trials in jRCT vs 5,068 in UMIN-CTR, April 2018–March 2020; registry differences | Published 2022; Japan |




